Solvonis Appoints Water Tower Research

Solvonis Therapeutics plc
(“Solvonis” or the “Company”)

Appoints Water Tower Research to deepen U.S. market understanding, refine Company profile and expand institutional investor reach

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system (“CNS”) disorders, is pleased to announce the appointment of Water Tower Research LLC (“Water Tower Research” or “WTR”) to support the Company in three areas of increasing importance: deepening its understanding of the evolving U.S. market environment, refining its corporate profile in that market, and broadening intuitional investor reach.

Water Tower Research (“WTR”) is a U.S.-based research and investor engagement firm. Under the engagement, WTR is expected to provide research coverage, supporting content and broader market-facing support. The agreed scope includes initiation of coverage reports, update notes, management series reports, fireside chats, podcasts and other research content. Content distribution is expected to take place through WTR’s network, including research aggregators, its website, direct channels and social media, with research and events available for investor access via the firm’s website and other distribution channels.

First, Solvonis believes the appointment will help deepen the Company’s understanding of the evolving U.S. market environment. Recent developments in the United States have underlined the importance of regulatory, policy and capital-markets momentum in CNS and neuropsychiatry, and the Company believes that understanding this backdrop is increasingly important as it advances its pipeline.

Second, the appointment is expected to help refine the Company’s profile in a market that is highly relevant to key programmes across the Solvonis pipeline, including SVN-002, its U.S.-focused programme in moderate-to-severe alcohol use disorder, SVN-015, its stimulant addiction programme, which has been accepted into the U.S. National Institute on Drug Abuse’s Addiction Treatment Discovery Program, and SVN-114, its lead PTSD candidate.

Third, Solvonis believes the appointment will help expand the Company’s institutional investor reach in the U.S. The United States remains the most important capital-markets arena for innovative CNS companies, and broader access to U.S. institutional investors is regarded as an important step in strengthening the Solvonis equity story.

Solvonis also believes there remains a substantial valuation gap between the Company and comparable U.S.-listed CNS peers. In that context, improving U.S. market understanding, sharpening the Company’s profile and broadening investor reach are all regarded as worthwhile steps in supporting the Company’s longer-term market positioning.

Anthony Tennyson, Chief Executive Officer of Solvonis, said: “Solvonis believes this appointment is an important and practical step in strengthening its position in the United States.

The U.S. is highly relevant both to key programmes across the pipeline and to the Company’s longer-term capital-markets ambition. Water Tower Research brings an established platform to help Solvonis better understand that market, refine its profile, and broaden investor reach.”

Enquiries:

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is an emerging biopharmaceutical company developing small-molecule therapeutics for high-burden central nervous system (CNS) disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and discovery-stage compounds across addiction and psychiatry.

The Company’s lead programmes target Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with additional development and discovery work supporting expansion into further addiction and psychiatric indications, including stimulant use disorder and depressive disorders.

Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK, while SVN-002 is preparing for a Phase 2b trial in the United States targeting moderate-to-severe AUD. The Company’s PTSD discovery programme has identified SVN-114 as a lead compound, emerging from a proprietary compound series designed to modulate key brain signalling systems associated with emotional processing and social behaviour.

In parallel, Solvonis is advancing proprietary CNS discovery programmes supported by a dedicated compound library to identify new small-molecule modulators of key neurotransmitter systems. This platform enables efficient early-stage innovation and supports the Company’s integrated approach to developing therapies across addiction and psychiatry.

With a capital-efficient development model and a focus on partnering opportunities, Solvonis aims to deliver sustained value through innovation in CNS therapeutics.

solvonis.com | LinkedIn | X (Twitter)